Table 2.
Summary of the impact of vLDX and vMPH on demographic characteristics of adults and children-adolescents with ADHD.
| Demographic characteristics | Children (6–12 years) | Adolescents (13–17 years) | Adults | |||
|---|---|---|---|---|---|---|
| vLDX | vMPH | vLDX | vMPH | vLDX | vMPH | |
| Age a (ρ) | Strong (−0.85) | Moderate (−0.53) | Moderate (−0.58) | – | – | – |
| BMI a (ρ) | Moderate (−0.53) | Weak (−0.49) | Moderate (−0.67) | – | Weak (−0.33) | – |
| Sex b | – | Male | Male | – | Female | Female |
Correlation strength (ρ) calculated using Pearson’s correlation method. False Discovery Rate (FDR) computed as Benjamini-Hochberg corrections for multiple testing. Statistically significant correlations were considered when FDR < 0.05 [if not significant, (−) is indicated]. Direction: positive correlation (ρ > 0) meant the higher the parameter result, the higher the efficacy; negative correlation (ρ < 0) meant the higher the parameter, the lower the efficacy. Strength: Strong: |ρ| ≥ 0.8; Moderate: 0.8 > |ρ| ≥ 0.5; Low: 0.5 > |ρ| ≥ 0.3; Negligible: |ρ| < 0.3 [not shown (−)].
Cohort displaying the highest efficacy. Calculated through unpaired two-tailed Student’s T test or Wilcoxon rank sum test, depending on the distribution in each cohort. FDR computed as Benjamini-Hochberg corrections for multiple testing. Only statistically significant results are shown [FDR < 0.05; if not significant, (−) is indicated].
ADHD, attention-deficit/hyperactivity disorder; BMI, body mass index; vLDX, virtual lisdexamfetamine; and vMPH, virtual methylphenidate.